Coherus BioSciences
Coherus BioSciences, a leading biologics firm, focuses on delivering quality biosimilar therapeutics globally.
Founded
2010Coherus BioSciences, a leading biologics firm, focuses on delivering quality biosimilar therapeutics globally.
Founded in Redwood City, Coherus BioSciences is a pioneering biologics company dedicated to expanding patient access to high-quality biosimilar therapeutics in regulated markets worldwide. The company's core mission is to deliver medicines that make a significant impact on people with life-altering diseases. Coherus offers a diversified portfolio of next-generation immuno-oncology therapies aimed at transforming cancer treatment and extending survival for patients with difficult-to-treat tumors.
Notable figures affiliated with Coherus BioSciences include industry-leading scientists and healthcare professionals. The company has garnered significant investment from prominent venture capital firms and strategic partners. Key achievements include the FDA approval of LOQTORZI™ (toripalimab-tpzi), an innovative therapy for recurrent cancer, marking a significant milestone in their mission to provide accessible and effective treatments. Coherus BioSciences continues to make a substantial impact in the biopharmaceutical industry, driving innovation and improving patient outcomes globally.
Companies similar to Coherus BioSciences include Z Squared, Clovis Oncology, Heron Therapeutics and Omeros.
Coherus BioSciences was founded in 2010.
Coherus BioSciences' headquarters is located in Redwood City, CA, US.
Coherus BioSciences' most recent funding round was for $50M (USD) in May 2023.
As of May 16, 2023, Coherus BioSciences has disclosed funding of $1.3B (USD). Undisclosed round amounts are excluded.
Coherus BioSciences has 359 employees as of Feb 6, 2024.
Omeros
omeros.com
